← Leaderboards
John P Fruehauf
University Of California Irvine
$364,580
Attributed
$543,917
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $207.2K · FY2009–13$250K$187.5K$125K$62.5K$0
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$543,917 · 5
By mechanism
R21$358,674 · 1
R43$99,701 · 1
P30$85,542 · 3
Top collaborators
- Krishnansu Sujata Tewari2 shared
Most similar at University Of California Irvine
Same institution · by research overlap
- Frank Louis Meyskens$19,843,890
- Christopher C. W. Hughes$22,189,863
- Orhan Nalcioglu$5,072,098
- Rene Hornung$24,634
- Arthur D Lander$24,994,474
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsSignal TransductionCervicalMalignant NeoplasmsFundingProgramsBiomarkerClinical ResearchAngiogenesis InhibitorsPrognosticTranslational ResearchNeoadjuvant TherapyGrowthJournalsLinkMissionNovel StrategiesComprehensive Cancer CenterCoupledCancer CareBreast MelanomaCollaborationsAreaBreast
Grant awards (8)
TRANSLATIONAL ONCOLOGY PROGRAM$19,111
P30 · FY2013 · CA · contact PI
Novel biologic markers of treatment resistance in locally advanced cervical carci$172,916
R21 · FY2012 · CA
Novel biologic markers of treatment resistance in locally advanced cervical carci$185,758
R21 · FY2011 · CA
TRANSLATIONAL ONCOLOGY PROGRAM$21,489
P30 · FY2011 · CA · contact PI
TRANSLATIONAL ONCOLOGY PROGRAM$22,704
P30 · FY2010 · CA · contact PI
TRANSLATIONAL ONCOLOGY PROGRAM$22,238
P30 · FY2009 · CA · contact PI
Genomics Screening for Antiangiogenesis Drugs$99,701
R43 · FY2002 · CA
CORE--CLINICAL TRIALS PROTOCOL REVIEW$0
P30 · FY2002 · CA